Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.

abstract：:We investigated the role of the leptin receptor (Ob-R) and its relationship with PI3K/AKT activation in diffuse large B-cell lymphoma (DLBCL) clinical samples followed by in vitro studies using a panel of CRC cell lines. Leptin exerts its physiological action through its receptor Ob-R. Overexpression of Ob-R has been ...

journal_title：Leukemia & lymphoma

authors： Uddin S,Bu R,Ahmed M,Hussain AR,Ajarim D,Al-Dayel F,Bavi P,Al-kuraya KS

更新日期：2010-07-01 00:00:00

abstract：:We treated 15 patients with therapy related acute nonlymphocytic leukemia (tANLL) or therapy related myelodysplastic syndrome (tMDS) who had no rearrangements of chromosomes 5 and/or 7 or complex cytogenetic rearrangements by intensive chemotherapy. The median age was 43 years. Seven patients had one of the "specific"...

journal_title：Leukemia & lymphoma

authors： Fenaux P,Laï JL,Quiquandon I,Preudhomme C,Dupriez B,Facon T,Lorthois C,Lucidarme D,Bauters F

更新日期：1991-01-01 00:00:00

abstract：:Classic Hodgkin lymphoma (cHL) is a unique lymphoid malignancy with an immunosuppressed tumor microenvironment. Increased PD-L1 expression on the malignant Hodgkin Reed Sternberg (HRS) cells due to genetic amplification at chromosome 9p24.1 is likely one of the primary mechanisms for this unique biology. For this reas...

journal_title：Leukemia & lymphoma

authors： Khurana A,Armand P,Ansell SM

更新日期：2020-05-01 00:00:00

abstract：:Current therapies for the treatment of malignancies are associated with significant limitations to the hematopoietic system since chemotherapy and radiation therapy do not discriminate between normal and malignant cells. Since bone marrow depression occurs at low to midlethal doses of irradiation, approaches to improv...

journal_title：Leukemia & lymphoma

authors： Zucali JR

更新日期：1994-03-01 00:00:00

abstract：:A clinical case of patient with a simultaneous gastrointestinal stromal tumors (GIST) and MALT lymphoma in relapse is presented. Simultaneous treatment with imatinib mesylate and rituximab was given, yielded response for both tumors and was well tolerated. ...

journal_title：Leukemia & lymphoma

authors： Bompas E,Velay B,Blay JY

更新日期：2004-11-01 00:00:00

abstract：:We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains of chromosome 1q (+1q). We retrospectively identified 95 patients, 21% having +1q. For patients with +1q, the overall response rate to induction was 85%, with 40% having...

journal_title：Leukemia & lymphoma

authors： Shah GL,Landau H,Londono D,Devlin SM,Kosuri S,Lesokhin AM,Lendvai N,Hassoun H,Chung DJ,Koehne G,Jhanwar SC,Landgren O,Levine R,Giralt SA

更新日期：2017-08-01 00:00:00

abstract：:The term high-risk multiple myeloma is aimed to identify a heterogeneous group of patients who are more likely to progress and die early of their disease. Therefore, recognition of these patients is crucial. With the increase in the number of treatment options, the outcome for high-risk patients has probably improved,...

journal_title：Leukemia & lymphoma

authors： Muchtar E,Magen H,Gertz MA

更新日期：2017-06-01 00:00:00

abstract：:The occurrence of unexplained peripheral blood cytopenia, particularly neutropenia, has been recently reported after rituximab. Its prevalence may be underestimated since it may occur late after treatment. This study analysed all cases of unexplained delayed-onset peripheral blood cytopenia of WHO grade II - IV occurr...

journal_title：Leukemia & lymphoma

authors： Cattaneo C,Spedini P,Casari S,Re A,Tucci A,Borlenghi E,Ungari M,Ruggeri G,Rossi G

更新日期：2006-06-01 00:00:00

abstract：:The relationship between histopathologic characteristics and treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy needs re-evaluation. Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednis...

journal_title：Leukemia & lymphoma

authors： Hong J,Park S,Park J,Kim HS,Kim KH,Ahn JY,Rim MY,Jung M,Sym SJ,Cho EK,Shin DB,Lee JH

更新日期：2011-10-01 00:00:00

abstract：:We measured histone deacetylase (HDAC) activity in 17 patients with primary myelofibrosis (PMF); 19 with other myeloproliferative neoplasm (MPN) and 16 normal volunteers. Significantly elevated HDAC levels were shown in patients with PMF compared with other MPN patients and normal volunteers (p<0.05). Sixteen patients...

journal_title：Leukemia & lymphoma

authors： Wang JC,Chen C,Dumlao T,Naik S,Chang T,Xiao YY,Sominsky I,Burton J

更新日期：2008-12-01 00:00:00

abstract：:We have identified a family in which three members developed B-cell lymphoproliferative disorders within a nine month period. The 33 year old proband and his mother have hairy cell leukemia, and his 37 year old brother developed a large cell lymphoma. Chromosomal fragile site analysis of peripheral blood lymphocytes o...

journal_title：Leukemia & lymphoma

authors： Moormeier JA,Neilly ME,Vardiman JW,Le Beau MM,Golomb HM

更新日期：1991-01-01 00:00:00

abstract：:Mini-transplant has been used popularly in recent years. The intensity of conditioning regimens is less in mini-transplant, thus the anti-tumor effect is mainly carried by an immunological reaction, called graft-versus-leukemia (GVL)/graft-versus-tumor (GVT) effect. Thus, graft-versus-host disease (GVHD) in mini-trans...

journal_title：Leukemia & lymphoma

authors： Mineishi S,Schuening FG

更新日期：2004-10-01 00:00:00

abstract：:The prognostic significance of specific cytogenetic abnormalities in follicular lymphoma (FL) is an area of ongoing research. A small percentage of FL are characterized by a polyploid karyotype. Several studies have analyzed ploidy level to determine its role as an independent prognostic factor in non-Hodgkins lymphom...

journal_title：Leukemia & lymphoma

authors： James GK,Horsman D,Connors JM,Klasa R,Wilson K,Argatoff L,Gascoyne RD

更新日期：1998-01-01 00:00:00

abstract：:Therapy with an immunotoxin, anti-Tac(Fv)-PE38, which is a conjugate of the variable domains of an anti-Tac monoclonal antibody and Pseudomonas exotoxin, was reported to be useful for adult T cell leukemia (ATL) patients but a considerable amount of the immunotoxin is needed for the therapy and some side effects were ...

journal_title：Leukemia & lymphoma

authors： Ohno N,Kreitman RJ,Saito T,Masamoto I,Uozumi K,Hanada S,Takeuchi S,Furukawa T,Sumizawa T,Arima T,Akiyama S

更新日期：2002-04-01 00:00:00

abstract：:Bone marrow toxicity is a great challenge for physicians treating patients with non-Hodgkin's lymphoma (NHL) and prescribed chemotherapy. Granulocyte colony-stimulating factor (G-CSF) prevents myelotoxicity, but the optimal timing and scheduling of G-CSF administration has not been ascertained. We investigated leukocy...

journal_title：Leukemia & lymphoma

authors： Sawada KI,Sato N,Kohno M,Hannda H,Yasukouchi T,Tanngo M,Hirayama A,Koike T

更新日期：1995-12-01 00:00:00

abstract：:To define the specific genetic alterations in nasal natural killer/T-cell lymphoma (N-NK/T-L), the assay of restriction landmark genomic scanning (RLGS), a genome-wide method, was used to investigate a pair of genomic DNA from N-NK/T-L cells and peripheral blood leukocytes of the same patient. The intensified spots in...

journal_title：Leukemia & lymphoma

authors： Ye Y,Li T,Zhang B,Guo Z

更新日期：2007-01-01 00:00:00

abstract：:Central venous access devices (CVADs) are used for intravenous therapy in patients with hematological malignancies. There are limited data comparing catheter outcomes in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. A retrospective review comparing the incidence of early and late CVAD-a...

journal_title：Leukemia & lymphoma

authors： Lim MY,Al-Kali A,Ashrani AA,Begna KH,Elliott MA,Hogan WJ,Hook CC,Kaufmann SH,Letendre L,Litzow MR,Patnaik MS,Pardanani A,Tefferi A,Wolanskyj AP,Grill DE,Pruthi RK

更新日期：2013-06-01 00:00:00

abstract：:Triptolide is a diterpenoid triepoxide purified from a Chinese herb Tripterygium Wilfordii Hook F (TWHF). TWHF has been used in traditional Chinese medicine for more than two thousand years. However, its potential value was recognized by the western medicine only after investigators observed the effectiveness of TWHF ...

journal_title：Leukemia & lymphoma

authors： Chen BJ

更新日期：2001-07-01 00:00:00

abstract：:To assess parameters of therapeutic response and survival after the onset of the blastic phase (BP) in 47 patients with Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML), a number of clinical hematologic, and cytogenetic data at the BP were evaluated. Among the eleven parameters examined, only the c...

journal_title：Leukemia & lymphoma

authors： Sadamori N,Yao E,Mine M,Tokunaga S,Matsunaga M,Nakamura H,Sasagawa I,Itoyama T,Kawachi T,Sandberg AA

更新日期：1991-01-01 00:00:00

abstract：:Large granular lymphocyte disorder (LGLD) is a lymphoproliferative disease, characterized by moderate lymphocytosis with an excess of large granular lymphocytes, neutropenia, anemia, and a variable, but mostly chronic clinical course. We describe two patients with LGLD. One patient presented with symptomatic corticost...

journal_title：Leukemia & lymphoma

authors： Peller S,Kaufman S,Rotter V

更新日期：1991-01-01 00:00:00

abstract：:Splenectomy specimens from 8 cases of chronic lymphocytic leukaemia (CLL) were examined. The infiltrate in the red pulp consisted predominantly of small lymphocytes. In contrast the predominant cells in the white pulp were pro-lymphocytes and para-immunoblasts. The Ki67 marker, which identifies cells in growth phase, ...

journal_title：Leukemia & lymphoma

authors： Lampert IA,Hegde U,Van Noorden S

更新日期：1990-01-01 00:00:00

abstract：:In order to determine the efficacy of the antifibrinolytic agent tranexamic acid (TA) in reducing bleeding and platelet transfusions during the treatment of acute myeloid leukemia (AML), we conducted a randomized placebo-controlled double-blind study. Patients with AML undergoing induction or postremission consolidati...

journal_title：Leukemia & lymphoma

authors： Shpilberg O,Blumenthal R,Sofer O,Katz Y,Chetrit A,Ramot B,Eldor A,Ben-Bassat I

更新日期：1995-09-01 00:00:00

abstract：:To define risk groups in children with acute myeloid leukaemia (AML), we conducted a multivariate stepwise Cox regression analysis of three consecutive multicentre studies in East Germany. The total number of patients was 240, but cytogenetics and remission status on day 15 were routinely investigated only in the most...

journal_title：Leukemia & lymphoma

authors： Steinbach D,Hermann J,Littlewood T,Zintl F

更新日期：2001-11-01 00:00:00

abstract：:The transcriptional factor SOX11 is a disease-defining antigen in mantle cell lymphoma (MCL) and absent in most non-malignant tissues. To explore the role of SOX11-related cell signaling, and potentially take benefit from these for targeted therapy, associated networks and proteins need to be defined. In this study, w...

journal_title：Leukemia & lymphoma

authors： Kuci V,Nordström L,Conrotto P,Ek S

更新日期：2016-08-01 00:00:00

abstract：:Multidrug resistance gene (mdr1) RNA levels were determined in 55, and P-glycoprotein expression in 37 samples of peripheral leukemic cells from 17 patients with acute myeloblastic leukemia (AML) and 7 patients with acute lymphocytic leukemia (ALL). Between sample collections, patients were treated with various chemot...

journal_title：Leukemia & lymphoma

authors： Gruber A,Areström I,Albertioni F,Björkholm M,Peterson C,Vitols S

更新日期：1995-08-01 00:00:00

abstract：:After a first course of induction chemotherapy, 30-40% of patients with acute myeloid leukemia (AML) do not achieve a complete response (CR). A second course of an anthracycline and intermediate-dose cytarabine (IDAC) allows a significant number of patients with persistent AML at day 14 to finally achieve a CR. We hyp...

journal_title：Leukemia & lymphoma

authors： Prébet T,Jean E,Autret A,Charbonnier A,Rey J,Etienne A,D'incan E,Fürst S,Arnoulet C,Blaise D,Vey N

更新日期：2012-11-01 00:00:00

abstract：:Imatinib, which has revolutionized chronic myeloid leukemia (CML) treatment, was suggested to improve lipid profile. Statins, a dyslipidemia drug, were reported to potentiate imatinib's antileukemic effect. However, analysis of imatinib combined with statins is lacking. We have retrospectively analyzed the normalizati...

journal_title：Leukemia & lymphoma

authors： Ellis M,Krashin E,Hamburger-Avnery O,Gan S,Elis A,Ashur-Fabian O

更新日期：2017-05-01 00:00:00

abstract：:Because of the lack of standard treatment in refractory and relapsed acute myelogenous leukemia (AML) several new drugs have been employed alone to evaluate their efficacy in this peculiar category of patient. Bisantrene, a new anthracene bishydrazone derivative, has shown antileukemic effect in phase I and II clinica...

journal_title：Leukemia & lymphoma

authors： Spadea A,Petti MC,Aloespiriti MA,Avvisati G,De Gregoris C,Fazi P,Latagliata R,Amadori S,Mandelli F

更新日期：1993-02-01 00:00:00

abstract：:Several studies have indicated that age, hemoglobin and serum albumin are among the most important prognostic factors for survival of patients with Waldenstrom's macroglobulinemia (WM). Furthermore, recent data indicate that serum b2-microglobulin may be also significant. The recently proposed International Staging Sy...

journal_title：Leukemia & lymphoma

authors： Dimopoulos M,Gika D,Zervas K,Kyrtsonis M,Symeonidis A,Anagnostopoulos A,Bourantas K,Matsouka C,Pangalis G

更新日期：2004-09-01 00:00:00

abstract：:To clarify the significance of post-transplant serum ferritin (SF), we retrospectively assessed pre- and post-transplant SF. Among 256 patients undergoing allogeneic stem cell transplant (SCT) for hematologic malignancies between 2000 and 2011, those who had relapsed within 1 year were excluded, and 110 patients survi...

journal_title：Leukemia & lymphoma

authors： Tachibana T,Tanaka M,Numata A,Matsumoto K,Tomita N,Fujimaki K,Taguchi J,Sakai R,Fujita H,Fujisawa S,Maruta A,Ishigatsubo Y,Kanamori H

更新日期：2014-06-01 00:00:00